Incannex Healthcare (IXHL) investor relations material

Executive summary

• Clinical-stage biopharma focused on oral fixed-dose combination therapies and psychedelic-assisted treatments for chronic conditions, with lead programs in obstructive sleep apnea (OSA), generalized anxiety disorder (GAD), and inflammatory diseases.

• IHL-42X (OSA) advanced through Phase 2, received FDA Fast Track, and is in a Phase 2 dose confirmation study (DREAMzz) to optimize dosing before Phase 3.

• PSX-001 (GAD) completed a Phase 2 trial showing significant efficacy and safety; next development steps under evaluation.

• IHL-675A (rheumatoid arthritis) Phase 2 trial terminated due to enrollment issues; future development strategies under review.

Financial highlights

• Net loss for FY 2026 was $19.3 million, a 59% improvement from $46.9 million in FY 2025, mainly due to lower financing-related losses and increased R&D tax incentives.

• R&D expenses decreased by $5.5 million year-over-year, reflecting the transition between clinical studies.

• General and administrative expenses increased by $4.7 million, driven by higher stock-based compensation and personnel costs.

• Cash and cash equivalents at June 30, 2026 were $67.7 million, up from $15.0 million a year earlier, supported by $78.7 million in share issuance proceeds.

• No revenue from product sales; minor revenue from clinic services in FY 2025 only.

Outlook and guidance

• Sufficient cash to fund operations for at least 12 months from the reporting date.

• Focus remains on advancing IHL-42X and PSX-001 through pivotal clinical milestones; IHL-675A development contingent on resource availability.

• Anticipate increased R&D and administrative expenses as clinical programs progress and commercialization preparations begin.